| 2024 | 2023 | 2022 | 2021 | 2018 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | -2,2 k € | -52.0% | -1,5 k € | -8.2% | -1,4 k € | +10.8% | -1,5 k € | +40.1% | -2,6 k € | -43.2% | -1,8 k € | -51.8% | -1,2 k € | +89.5% | -11,2 k € | -2702.0% | -398,4 € | +68.1% | -1,3 k € | -155.1% | -490,1 € | +85.1% | -3,3 k € | -844.7% | -347,5 € | +56.0% | -790,1 € | +20.5% | -994,3 € | |
| EBITDA | -2,2 k € | -52.0% | -1,5 k € | -8.2% | -1,4 k € | +10.8% | -1,5 k € | +40.1% | -2,6 k € | -35.1% | -1,9 k € | -47.5% | -1,3 k € | +88.6% | -11,3 k € | -2212.3% | -487,4 € | +69.7% | -1,6 k € | -227.8% | -490,1 € | +85.1% | -3,3 k € | -652.1% | -436,5 € | +50.3% | -879,1 € | +11.6% | -994,3 € | |
| Operating profit | -2,2 k € | -52.0% | -1,5 k € | -8.2% | -1,4 k € | +10.8% | -1,5 k € | +40.1% | -2,6 k € | -35.1% | -1,9 k € | -47.5% | -1,3 k € | +88.6% | -11,3 k € | -2212.3% | -487,4 € | +69.7% | -1,6 k € | -227.8% | -490,1 € | +85.1% | -3,3 k € | -652.1% | -436,5 € | +50.3% | -879,1 € | +11.6% | -994,3 € | |
| Profit/loss | -2,3 k € | -50.4% | -1,5 k € | -7.1% | -1,4 k € | +11.6% | -1,6 k € | +37.8% | -2,6 k € | -35.6% | -1,9 k € | -44.2% | -1,3 k € | +88.3% | -11,3 k € | -1366.4% | -770,6 € | +57.7% | -1,8 k € | -384.8% | 640,2 € | +101.2% | -55,5 k € | -12240.6% | -449,5 € | +49.7% | -894,2 € | +22.1% | -1,1 k € | |
| Equity | -226,4 k € | -1.0% | -224,1 k € | -0.7% | -222,6 k € | -0.6% | -221,1 k € | -1.8% | -217,3 k € | -42.3% | -152,7 k € | -1.3% | -150,8 k € | -0.9% | -149,5 k € | -8.2% | -138,2 k € | -0.6% | -137,4 k € | -1.3% | -135,6 k € | +28.0% | -188,4 k € | -41.7% | -132,9 k € | -0.3% | -132,5 k € | -0.7% | -131,6 k € | |
| Total assets | 733,6 € | +82.4% | 402,2 € | -5.0% | 423,2 € | -49.8% | 842,9 € | -28.2% | 1,2 k € | +2104.7% | 53,3 € | -69.5% | 174,7 € | -86.6% | 1,3 k € | +325.7% | 306,9 € | -70.6% | 1,0 k € | — | 990,7 € | +781.4% | 112,4 € | -10.4% | 125,4 € | -10.7% | 140,5 € | |||
| Cash | 733,6 € | +82.4% | 402,2 € | -5.0% | 423,2 € | -49.8% | 842,9 € | -28.2% | 1,2 k € | +2104.7% | 53,3 € | -69.5% | 174,7 € | -86.6% | 1,3 k € | +325.7% | 306,9 € | -70.6% | 1,0 k € | — | 990,7 € | +781.4% | 112,4 € | -10.4% | 125,4 € | -10.7% | 140,5 € | |||
| Debts | 227,1 k € | +1.2% | 224,5 k € | +0.7% | 223,0 k € | +0.5% | 222,0 k € | +1.6% | 218,5 k € | +43.0% | 152,7 k € | +1.2% | 151,0 k € | +0.3% | 150,5 k € | +8.9% | 138,2 k € | +0.1% | 138,0 k € | +1.8% | 135,6 k € | -28.4% | 189,4 k € | +42.4% | 133,0 k € | +0.3% | 132,6 k € | +0.7% | 131,7 k € | |
Private company with limited liability · Bruxelles · incorporated on 19/06/2003
Private company with limited liability loss-making in the latest fiscal year. Cash position rising (+82.4%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
JUVISE PHARMACEUTICAL is a Private company with limited liability incorporated in 2003. Its registered office is in Bruxelles.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette